Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714218 · ClinicalTrials.gov registry record · Phase 3
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 387
- Enrollment target
NCT02714218: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT02714218 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 387 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02714218, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 387 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
Primary Outcome
The percentage of participants who experienced at least 1 AE of Grade 3 or higher, judged to be related to study drug by the investigator, and with onset on or after the first dose of study treatment and within 30 days of the last dose of study treatment. AE grade was defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0 criteria.
Interventions
- BIOLOGICAL Nivolumab 3 mg/kg IV
- BIOLOGICAL Ipilimumab 1 mg/kg IV
- BIOLOGICAL Nivolumab 1 mg/kg IV
- BIOLOGICAL Ipilimumab 3 mg/kg IV
- BIOLOGICAL Nivolumab 6 mg/kg IV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 387 participants |
| Start Date | 2016-04-04 |
| Est. Completion | 2021-05-28 |
| Phase | Phase 3 |
What the finished NCT02714218 record still lists
NCT02714218 is an interventional study that assigns participants to a tested intervention. The registered 387 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 5 interventions - of which Nivolumab 3 mg/kg IV is the first listed.
NCT02714218 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02714218 about?
NCT02714218 is a clinical study titled "A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma". The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
What is the current status of trial NCT02714218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 387 participants. The study started on 2016-04-04. Estimated completion is 2021-05-28.
What interventions are being tested in trial NCT02714218?
The interventions under investigation include: Nivolumab 3 mg/kg IV (BIOLOGICAL), Ipilimumab 1 mg/kg IV (BIOLOGICAL), Nivolumab 1 mg/kg IV (BIOLOGICAL), Ipilimumab 3 mg/kg IV (BIOLOGICAL), Nivolumab 6 mg/kg IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT02714218?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02714218's enrollment target sits among peer trials
387 973rd of 2000 higher than 1,028 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03761108 · 387 participants · Phase 1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- NCT05572632 · 387 participants · NA
Rehabilitation in Safety-net Environments (RISE) to Improve Outcomes in Vulnerable Patients With COPD
- NCT06917079 · 387 participants · Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- NCT04092010 · 388 participants · NA
Improving Preschool Outcomes by Addressing Maternal Depression in Head Start
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI